within Pharmacolibrary.Drugs.ATC.C;

model C04AA01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.3,
    Cl             = 15 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,
    adminCount     = 1,
    Vd             = 0.002,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0016666666666666668,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Isoxsuprine is a vasodilator and beta-adrenergic agonist primarily used in the past to manage peripheral vascular diseases such as arteriosclerosis obliterans and Raynaud's phenomenon, as well as to prevent preterm labor due to its uterine relaxant effects. Its clinical use has significantly declined and it is not widely approved or commonly prescribed in contemporary medicine.</p><h4>Pharmacokinetics</h4><p>No detailed pharmacokinetic model parameters have been reported in accessible scientific literature for isoxsuprine in humans. Estimates provided below are based on general pharmacokinetic properties of similar vasoactive beta-agonists and uterine relaxants.</p><h4>References</h4><ol><li><p>Marzo, A, et al., &amp; Cantoni, V (2009). Pharmacokinetics of isoxsuprine hydrochloride administered orally and intramuscularly to female healthy volunteers. <i>Arzneimittel-Forschung</i> 59(9) 455–460. DOI:<a href=&quot;https://doi.org/10.1055/s-0031-1296425&quot;>10.1055/s-0031-1296425</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/19856793/&quot;>https://pubmed.ncbi.nlm.nih.gov/19856793</a></p></li><li><p>Erkert, RS, &amp; Macallister, CG (2002). Isoxsuprine hydrochloride in the horse: a review. <i>Journal of veterinary pharmacology and therapeutics</i> 25(2) 81–87. DOI:<a href=&quot;https://doi.org/10.1046/j.1365-2885.2002.00386.x&quot;>10.1046/j.1365-2885.2002.00386.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12000527/&quot;>https://pubmed.ncbi.nlm.nih.gov/12000527</a></p></li><li><p>Harkins, JD, et al., &amp; Tobin, T (1998). Absence of detectable pharmacological effects after oral administration of isoxsuprine. <i>Equine veterinary journal</i> 30(4) 294–299. DOI:<a href=&quot;https://doi.org/10.1111/j.2042-3306.1998.tb04100.x&quot;>10.1111/j.2042-3306.1998.tb04100.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9705111/&quot;>https://pubmed.ncbi.nlm.nih.gov/9705111</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C04AA01;
